Net Present Value Model: Sutent
Powered by ![]()
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model

Sutent Drug Details
Sunitinib malate (Sutent, SU011248) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Sunitinib malate is indicated for the treatment of gastrointestinal stromal tumors (GIST), advanced cholangiocarcinoma, renal cell carcinoma, islet cell carcinoma, pancreatic neuroendocrine tumor and metastatic renal cell carcinoma.The drug candidate is under development for the treatment of renal cell carcinoma as an adjuvant therapy, refractory or progressive high grade glioma and ependymoma tumors, thymoma, thymic carcinoma, metastatic mucosal or acral lentiginous melanoma, cholangiocarcinoma, uveal melanoma, follicular thyroid cancer, papillary thyroid cancer, recurrent glioblastoma multiforme, unresectable malignant pheochromocytoma, and paraganglioma. It was also under development for HER2- breast cancer, HER-2 positive breast cancer, triple-negative breast cancer, metastatic hepatocellular carcinoma, metastatic breast cancer, non-small cell lung cancer, transitional cell carcinoma of bladder, small-cell lung cancer, anaplastic astrocytoma, prostate cancer, colorectal cancer, soft tissue sarcoma including liposarcoma, metastatic melanoma, leiomyosarcoma, pediatric GIST, fibrosarcoma, malignant fibrous histiocytoma, meningioma, meurofibromatoses type I and II, Von Hippel-Lindau syndrome and germ cell tumors as third line therapy.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
| Quick View – Ociperlimab NPV Data | |||
| Drug Name |
|
||
| Administration Pathway |
|
||
| Therapeutic Areas |
|
||
| Key Manufacturers |
|
||
| Drug Development Status |
|
||

Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports